Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

AIM: Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), is known to be associated with type 2 diabetes mellitus (T2DM) in high rate. The improvement in hepatic function due to sodium-glucose co-transporter 2 (SGLT2) inhibitors has been reported in T2DM patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Seko, Yuya, Nishikawa, Taichiro, Umemura, Atsushi, Yamaguchi, Kanji, Moriguchi, Michihisa, Yasui, Kohichiroh, Kimura, Mayumi, Iijima, Hiroaki, Hashimoto, Toshio, Sumida, Yoshio, Okanoue, Takeshi, Itoh, Yoshito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267487/
https://www.ncbi.nlm.nih.gov/pubmed/30568471
http://dx.doi.org/10.2147/DMSO.S184767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267487/
https://www.ncbi.nlm.nih.gov/pubmed/30568471
http://dx.doi.org/10.2147/DMSO.S184767

Ejemplares similares